US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chromocell Therapeutics Corp

13.50

0.0000

Volume:- -

Turnover:- -

Market Cap:87.55M

PE:-10.88

High:13.50

Open:13.50

Low:13.50

Close:13.50

Loading ...

Overview Company News Filings

LGND: Pelthos To Become Public Company

Zacks Small Cap Research

Press Release: SJW Group Appoints Kay R. New as Chief Human Resources Officer

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings

Dow Falls Over 1%; US Initial Jobless Claims Decline

Ligand to Combine Pelthos Unit With Channel Therapeutics

Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics

MT Newswires Live

BRIEF-Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics

Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics

THOMSON REUTERS

Channel Therapeutics Corp - Upon Completion of Deal, Plesha to Become CEO of Combined Co and Knuettel to Become CFO

THOMSON REUTERS

Channel Therapeutics Corp - Proposed Transaction Will Raise $50 Mln in Equity Capital

THOMSON REUTERS

Channel Therapeutics Corp -Combined Co to Operate Under Name Pelthos Therapeutics Inc., Trade on Nyse American Exchange Under Ticker Pths

THOMSON REUTERS

Channel Therapeutics Corp - Ligand Is Entitled to a 13% Royalty on Worldwide Sales of Zelsuvmi

THOMSON REUTERS

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity

Rotork CHRO Acquires Company Shares, Signaling Market Confidence

SAIC appoints Kathleen McCarthy as CHRO

Press Release: Caterpillar Announces Appointment of Executive Officer, Chief Human Resources Officer Christy Pambianchi

Village Farms International Appoints Yvonne Trupiano as Global CHRO to Drive Expansion

Village Farms announces hiring of Trupiano as EVP, global CHRO

Press Release: Village Farms International Welcomes Yvonne Trupiano as Global Chief Human Resources Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CHRO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHRO\",,,,,undefined,":{"symbol":"CHRO","market":"US","secType":"STK","nameCN":"Chromocell Therapeutics Corp","latestPrice":13.5,"timestamp":1751562000000,"preClose":13.5,"halted":8,"volume":0,"delay":0,"floatShares":2510100,"shares":6485007,"eps":-1.240475,"marketStatus":"Early Closed","change":0,"latestTime":"07-03 13:00:00 EDT","open":13.5,"high":13.5,"low":13.5,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.240475,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":6,"symbolChange":{"newSymbol":"PTHS","executeDate":"2025-07-02"},"adr":0,"listingDate":1708059600000,"exchange":"AMEX","adjPreClose":13.5,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHRO\",,,,,undefined,":{"symbol":"CHRO","floatShares":2510100,"roa":"-188.95%","roe":"-26.00%","lyrEps":-1.427101,"shares":6485007,"dividePrice":0,"high":13.5,"amplitude":0,"preClose":13.5,"low":13.5,"week52Low":0.45,"pbRate":"-20.87","week52High":13.5,"institutionHeld":0,"latestPrice":13.5,"eps":-1.240475,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.240475,"open":13.5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHRO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529689290","title":"LGND: Pelthos To Become Public Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2529689290","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529689290?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:10","pubTimestamp":1745399400,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals, Inc.  announced that it had identified a suitor to take its subsidiary Pelthos Therapeutics public in an April 17thpress release. Ligand’s subsidiary will combine with the public company Channel Therapeutics  which is a clinical stage life sciences company developing pain therapeutics. Alongside the merger agreement, there will be a $50.1 million private investment in public equity  that is set to close just prior to the consummation of the merger. It will include an $18 million contribution from Ligand and $32 million from other investors.Readers may recall that Pelthos offers Zelsuvmi, an FDA approved treatment for molluscum contagiosum. Since the acquisition of Novan by Ligand in 2023, Zelsuvmi has received FDA approval, Pelthos was created and CEO was appointed to the company. In the last few quarters, Pelthos has been building inventory and preparing for commercial launch. Now that the pathway to being public has been clarified, Pelthos is interacting with ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lgnd-pelthos-become-public-company-091000998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4127","BK4007","CHRO","LGND","LU1559883803.SGD","LU0566484027.USD","PIPE","MC","LU1878469433.USD","BK4139"],"gpt_icon":0},{"id":"2529016008","title":"Press Release: SJW Group Appoints Kay R. New as Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529016008","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529016008?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:15","pubTimestamp":1745241300,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., April 21, 2025  -- SJW Group , a leading national investor-owned pure-play water and wastewater utility, today announced that its board of directors has appointed Kay R. New as chief human resources officer , effective immediately. In her new role, New will oversee enterprise-wide efforts related to talent development, organizational effectiveness, employee engagement and performance.\"Kay is an outstanding utility executive whose experience uniting teams, building high-performance cultures, and leading employee-focused initiatives at a national scale makes her an ideal fit for SJW Group,\" stated Eric W. Thornburg, chair, president and chief executive officer. \"Her deep expertise in human resources strategy, business acumen, and purposeful leadership will further strengthen our ability to empower teams, enhance performance, and deliver on our mission to provide high-quality water and exceptional service to our communities.\". SJW Group is among the largest investor-owne","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SJW","CHRO","BK4139","BK4172"],"gpt_icon":0},{"id":"2528728424","title":"Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2528728424","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528728424?lang=en_us&edition=fundamental","pubTime":"2025-04-18 00:09","pubTimestamp":1744906149,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44870357/gold-falls-over-1-dr-horton-posts-downbeat-earnings","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRO","RTC","CWD","ADGM","GPN","DHI","LGND"],"gpt_icon":1},{"id":"2528745870","title":"Dow Falls Over 1%; US Initial Jobless Claims Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2528745870","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528745870?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:58","pubTimestamp":1744898299,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6a27bb69de7b77a624049dad1cefcd82","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44864892/dow-falls-over-1-us-initial-jobless-claims-decline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","TSYW.SI","BK4130","ADGM","QLD","CHRO","CWD","LU1559883803.SGD","IOTR","MNQmain","TQQQ","QID","BK4135","NQmain","CLIK","NVIW.SI","LGND","LU0566484027.USD","SQQQ","BK4023","USJW.SI","RTC","BK4007","BK4090","USAW.SI","BK4139",".IXIC","BK4082"],"gpt_icon":1},{"id":"2528418713","title":"Ligand to Combine Pelthos Unit With Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528418713","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528418713?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:31","pubTimestamp":1744889460,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals has struck a deal to combine its Pelthos Therapeutics unit with Channel Therapeutics in a bid to accelerate the commercialization of its Zelsuvmi treatment for molluscum contagiosum infections.Ligand on Thursday said it will invest $18 million in the combined company, which will operate as Pelthos Therapeutics, while a group led by investment firm Murchinson will chip in an additional $32 million.Channel, a Freehold, N.J., clinical-stage biotechnology company that had a market capitalization of around $7.7 million based on Thursday's closing share price of $1.26, said its shareholders will own about 7.7% of the combined company, while Ligand will own about 55% and the other investors will own roughly 37%.Channel shares were recently up nearly 20% at $1.50 in premarket trading.The U.S. Food and Drug Administration in January 2024 approved Zelsuvmi as the first novel drug for the treatment of molluscum contagiosum, a highly contagious viral skin infection.Jupiter, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","LGND","LENZ","CHRO","LU0566484027.USD","BK4139"],"gpt_icon":0},{"id":"2528923527","title":"Ligand Pharmaceuticals to Merge Units With Channel Therapeutics to Launch Pelthos Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528923527","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528923527?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:37","pubTimestamp":1744886232,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals  and Channel Therapeutics  said Thursday they have agreed to merge Ligand's Pelthos Therapeutics and LNHC subsidiaries with Channel's CHRO Merger Sub in a deal worth $50 million.Upon the expected summer 2025 completion of the transaction, the new company will operate under the name Pelthos Therapeutics and trade on the New York Stock Exchange under the ticker symbol \"PTHS,\" the companies said.The merger will be backed by $50 million in capital raised from a group of investors that includes Ligand and a group of investors led by Murchinson, the companies said.The new company will initially focus on commercializing Pelthos' US Food and Drug Administration-approved Zelsuvmi topical gel for the treatment of Molluscum contagiosum, a contagious skin infection, the companies said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","LU0566484027.USD","CHRO","LGND","BK4007","BK4139","LU1559883803.SGD"],"gpt_icon":0},{"id":"2528791843","title":"BRIEF-Ligand Subsidiary Pelthos Therapeutics To Combine With Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528791843","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528791843?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:06","pubTimestamp":1744884371,"startTime":"0","endTime":"0","summary":"BRIEF-Ligand Subsidiary Pelthos Therapeutics To Combine With Channel TherapeuticsApril 17 (Reuters) - Channel Therapeutics Corp CHRO.A:LIGAND SUBSIDIARY PELTHOS THERAPEUTICS TO COMBINE WITH CHANNEL TH","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","LU0566484027.USD","LGND","CHRO","BK4007","BK4139"],"gpt_icon":0},{"id":"2528993797","title":"Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528993797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528993797?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHRO","LU1559883803.SGD","LGND","LU0566484027.USD","BK4139","BK4007"],"gpt_icon":0},{"id":"2528799951","title":"Channel Therapeutics Corp - Upon Completion of Deal, Plesha to Become CEO of Combined Co and Knuettel to Become CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2528799951","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528799951?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU1559883803.SGD","LGND","BK4139","CHRO","LU0566484027.USD"],"gpt_icon":0},{"id":"2528799530","title":"Channel Therapeutics Corp - Proposed Transaction Will Raise $50 Mln in Equity Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2528799530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528799530?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CHRO","LU0566484027.USD","BK4007","LU1559883803.SGD","LGND"],"gpt_icon":0},{"id":"2528612799","title":"Channel Therapeutics Corp -Combined Co to Operate Under Name Pelthos Therapeutics Inc., Trade on Nyse American Exchange Under Ticker Pths","url":"https://stock-news.laohu8.com/highlight/detail?id=2528612799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528612799?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CHRO","LGND","LU1559883803.SGD","BK4007","LU0566484027.USD"],"gpt_icon":0},{"id":"2528582799","title":"Channel Therapeutics Corp - Ligand Is Entitled to a 13% Royalty on Worldwide Sales of Zelsuvmi","url":"https://stock-news.laohu8.com/highlight/detail?id=2528582799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528582799?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884042,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QU2LG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","BK4139","BK4007","LU1559883803.SGD","LGND","CHRO"],"gpt_icon":0},{"id":"2528079969","title":"Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2528079969","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528079969?lang=en_us&edition=fundamental","pubTime":"2025-04-17 18:00","pubTimestamp":1744884000,"startTime":"0","endTime":"0","summary":"Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos’ ZELSUVMI. ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers. Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI. Frank Knuettel II, CEO of Channel Therapeutics, commented, “We are very excited about the merger with Pelthos. We have performed extensive due diligence on the ZELSUVMI market opportunity and their team and o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ligand-subsidiary-pelthos-therapeutics-combine-100000828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","LU1559883803.SGD","CHRO","LENZ","LGND","LU0566484027.USD"],"gpt_icon":0},{"id":"2528799676","title":"EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity","url":"https://stock-news.laohu8.com/highlight/detail?id=2528799676","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528799676?lang=en_us&edition=fundamental","pubTime":"2025-04-17 17:45","pubTimestamp":1744883135,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals Incorporated  and Channel Therapeutics Corporation  on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc.  with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel.The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson.Under the merger agreement, Channel will acquire 100% of Pelthos’ issued and outstanding equity interests, change its name to Pelthos Therapeutics, and trade on the NYSE American exchange under the ticker PTHS.Upon completing the transaction, Scott Plesha, CEO of Pelthos, will become CEO of the combined company, and Frank Knuettel II, CEO of Channel Therapeutics, will become CFO. The transaction is expected to close in the summer of 2025.The combined company will initially focus on accelerating the commercialization of Pelthos’ Zelsuvmi  topical gel, 10.3%, for Molluscum contagiosum infections in adu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exclusive-ligand-subsidiary-pelthos-therapeutics-094535653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","LU0566484027.USD","CHRO","BK4139","LU1559883803.SGD","LGND","MDCO"],"gpt_icon":0},{"id":"2526955006","title":"Rotork CHRO Acquires Company Shares, Signaling Market Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2526955006","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526955006?lang=en_us&edition=fundamental","pubTime":"2025-04-11 22:03","pubTimestamp":1744380189,"startTime":"0","endTime":"0","summary":"Rotork plc ( ($GB:ROR) ) just unveiled an update. Rotork plc announced that Beatriz Rodriguez Gomez, the Chief Human Resources Officer, has purchas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rotork-chro-acquires-company-shares-signaling-market-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rotork-chro-acquires-company-shares-signaling-market-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CHRO"],"gpt_icon":0},{"id":"2526393435","title":"SAIC appoints Kathleen McCarthy as CHRO","url":"https://stock-news.laohu8.com/highlight/detail?id=2526393435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526393435?lang=en_us&edition=fundamental","pubTime":"2025-04-09 22:35","pubTimestamp":1744209333,"startTime":"0","endTime":"0","summary":"Science Applications International announced the appointment of Kathleen McCarthy as the company’s new Executive Vice President and Chief Human Res...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/saic-appoints-kathleen-mccarthy-as-chro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/saic-appoints-kathleen-mccarthy-as-chro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4123","CHRO","SAIC"],"gpt_icon":0},{"id":"2524254098","title":"Press Release: Caterpillar Announces Appointment of Executive Officer, Chief Human Resources Officer Christy Pambianchi","url":"https://stock-news.laohu8.com/highlight/detail?id=2524254098","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524254098?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:00","pubTimestamp":1743685200,"startTime":"0","endTime":"0","summary":"IRVING, Texas, April 3, 2025 /PRNewswire/ -- Caterpillar Inc.  today announced the appointment of Christy Pambianchi to Chief Human Resources Officer  effective May 1. Pambianchi will be a member of Caterpillar's Executive Office and will succeed Cheryl H. Johnson, whose retirement was announced in January.Pambianchi has served as a CHRO for the past 18 years at various companies across multiple industries, most recently serving as Chief People Officer at Intel, a global leader in semiconductor design and manufacturing with over $53 billion in annual revenue.\"Our people are a source of innovation and competitive advantage, and we must continue to attract and retain the best talent to serve our customers,\" said Caterpillar Chairman and CEO Jim Umpleby. \"Christy is an experienced executive with strong credentials and a history of demonstrated success. I am confident she will contribute to our journey of profitable growth.\". Pambianchi holds a bachelor's degree from Cornell University's S","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4605","LU0868494617.USD","BK4512","CHRO","LU2264538146.SGD","LU0081259029.USD","LU1064131342.USD","LU2023250504.SGD","BK4533","IE00BSNM7G36.USD","BK4527","BK4602","IE00BD6J9T35.USD","LU0942090050.USD","BK4550","BK4612","BK4543","LU1917777945.USD","LU1974910355.USD","BK4141","BK4579","CAT","BK4585","LU2106854487.HKD","LU1988902786.USD","LU2237438978.USD","BK4520","BK4554","BK4515","BK4597","BK4588","BK4575","BK4535","BK4139","BK4529","LU0321505439.SGD","BK4516","BK4149","LU0321505868.SGD","LU0868494708.USD","BK4534"],"gpt_icon":1},{"id":"2523945118","title":"Village Farms International Appoints Yvonne Trupiano as Global CHRO to Drive Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945118","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945118?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:53","pubTimestamp":1743421984,"startTime":"0","endTime":"0","summary":"The latest update is out from Village Farms International ( ($VFF) ). Village Farms International has appointed Yvonne Trupiano as the new Executiv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/village-farms-international-appoints-yvonne-trupiano-as-global-chro-to-drive-expansion?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/village-farms-international-appoints-yvonne-trupiano-as-global-chro-to-drive-expansion?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CHRO"],"gpt_icon":0},{"id":"2523107359","title":"Village Farms announces hiring of Trupiano as EVP, global CHRO","url":"https://stock-news.laohu8.com/highlight/detail?id=2523107359","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523107359?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:15","pubTimestamp":1743419746,"startTime":"0","endTime":"0","summary":"Village Farms (VFF) International announced the hiring of Yvonne Trupiano as the Company’s Executive Vice President, EVP, and Global Chief Human Re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/village-farms-announces-hiring-of-trupiano-as-evp-global-chro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/village-farms-announces-hiring-of-trupiano-as-evp-global-chro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VFF","BK4139","EVP","BK4189","CHRO"],"gpt_icon":0},{"id":"2523031912","title":"Press Release: Village Farms International Welcomes Yvonne Trupiano as Global Chief Human Resources Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523031912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523031912?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"-- Former consumer goods distribution, food, and retail service industry executive will help guide the Company's global expansion initiatives --. Ms. Trupiano brings over 25 years of experience primarily leading HR functions for public and private companies across various industries and sizes, with the majority of her career at Fortune 500 global companies Avis Budget Group and SpartanNash. She began her career at a privately held automotive supplier and most recently served as CHRO at a large insurance company. She is a results-oriented business leader and transformation expert with proven success assessing human capital needs to deliver successful outcomes for current and future business goals. She takes pride in leading purpose driven, consumer centric organizations, and is an accomplished builder of high-performing teams.Village Farms leverages decades of experience as a large-scale, Controlled Environment Agriculture-based, vertically integrated supplier for high-value, high-growt","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACB","BK4557","CHRO","BK4139","BK4189","BK4007","VFF"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHRO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-07-02","symbol":"CHRO","defaultRemindTime":1751463000000,"type":"split","dateTimestamp":1751428800000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-07-02","symbol":"CHRO","oldSymbol":"CHRO","defaultRemindTime":1751463000000,"newSymbol":"PTHS","exchange":"AMEX","type":"symbolChange","dateTimestamp":1751428800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHRO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CHRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CHRO","date":"2025-06-30","current":-1.189405,"percent":0.266254,"low":-7.431441,"twenty":-1.324869,"median":-0.918643,"eighty":-0.454385,"high":-0.323812,"avg":-1.218748,"sd":1.186262,"marketCap":8754759},"quantilePoints":[{"date":"2024-02-16","current":-7.431441,"twenty":-7.431441,"median":-7.431441,"eighty":-7.431441,"marketCap":34177704},{"date":"2024-02-23","current":-6.019507,"twenty":-6.301894,"median":-5.994425,"eighty":-5.828056,"marketCap":27684120},{"date":"2024-03-01","current":-4.727821,"twenty":-5.999441,"median":-5.629076,"eighty":-4.958568,"marketCap":21743569},{"date":"2024-03-08","current":-4.539711,"twenty":-5.86133,"median":-5.016255,"eighty":-4.479516,"marketCap":20878440},{"date":"2024-03-15","current":-4.238736,"twenty":-5.828056,"median":-4.640036,"eighty":-4.238736,"marketCap":19494234},{"date":"2024-03-22","current":-3.486297,"twenty":-5.509688,"median":-4.489549,"eighty":-4.100889,"marketCap":16033719},{"date":"2024-03-28","current":-3.398513,"twenty":-5.332279,"median":-4.32652,"eighty":-3.722062,"marketCap":15629992},{"date":"2024-04-05","current":-2.934509,"twenty":-5.11658,"median":-4.198982,"eighty":-3.225452,"marketCap":13496008},{"date":"2024-04-12","current":-2.295564,"twenty":-4.843195,"median":-4.100914,"eighty":-3.039851,"marketCap":10557454},{"date":"2024-04-19","current":-0.975552,"twenty":-4.712772,"median":-3.868787,"eighty":-2.801578,"marketCap":7200347},{"date":"2024-04-26","current":-1.194553,"twenty":-4.627495,"median":-3.486297,"eighty":-2.39777,"marketCap":8816752},{"date":"2024-05-03","current":-1.385682,"twenty":-4.55476,"median":-3.210403,"eighty":-1.424176,"marketCap":10227432},{"date":"2024-05-10","current":-1.409573,"twenty":-4.509614,"median":-3.084997,"eighty":-1.409573,"marketCap":10403767},{"date":"2024-05-17","current":-1.316144,"twenty":-4.459376,"median":-3.003483,"eighty":-1.403202,"marketCap":11814448},{"date":"2024-05-24","current":-0.929813,"twenty":-4.371616,"median":-2.871806,"eighty":-1.319641,"marketCap":8346525},{"date":"2024-05-31","current":-0.929813,"twenty":-4.291406,"median":-2.506623,"eighty":-1.259855,"marketCap":8346525},{"date":"2024-06-07","current":-0.969101,"twenty":-4.238736,"median":-2.385856,"eighty":-1.203901,"marketCap":8699195},{"date":"2024-06-14","current":-0.883977,"twenty":-4.222834,"median":-2.155189,"eighty":-1.121113,"marketCap":7935077},{"date":"2024-06-21","current":-1.014937,"twenty":-4.159228,"median":-1.641577,"eighty":-0.982197,"marketCap":9110644},{"date":"2024-06-28","current":-0.89046,"twenty":-4.155917,"median":-1.508981,"eighty":-0.975591,"marketCap":7993267},{"date":"2024-07-05","current":-0.818497,"twenty":-4.140944,"median":-1.441428,"eighty":-0.931673,"marketCap":7347293},{"date":"2024-07-12","current":-0.825045,"twenty":-4.100889,"median":-1.409653,"eighty":-0.924575,"marketCap":7406072},{"date":"2024-07-15","current":-0.753018,"twenty":-4.100864,"median":-1.409613,"eighty":-0.911479,"marketCap":6759510},{"date":"2024-08-02","current":-0.687538,"twenty":-4.100839,"median":-1.409573,"eighty":-0.898383,"marketCap":6171726},{"date":"2024-08-09","current":-0.448275,"twenty":-3.995448,"median":-1.389664,"eighty":-0.877429,"marketCap":4023965},{"date":"2024-08-16","current":-0.483077,"twenty":-3.8575,"median":-1.321973,"eighty":-0.848618,"marketCap":4731657},{"date":"2024-08-23","current":-0.510034,"twenty":-3.676915,"median":-1.282154,"eighty":-0.822426,"marketCap":4995695},{"date":"2024-08-30","current":-0.535762,"twenty":-3.526427,"median":-1.242336,"eighty":-0.784448,"marketCap":5247700},{"date":"2024-09-06","current":-0.544711,"twenty":-3.451183,"median":-1.217924,"eighty":-0.690157,"marketCap":5335354},{"date":"2024-09-13","current":-0.576739,"twenty":-3.353367,"median":-1.168814,"eighty":-0.569957,"marketCap":5649063},{"date":"2024-09-20","current":-0.512742,"twenty":-3.225452,"median":-1.086965,"eighty":-0.542874,"marketCap":5022222},{"date":"2024-09-27","current":-0.600525,"twenty":-3.130144,"median":-0.978923,"eighty":-0.535762,"marketCap":5882038},{"date":"2024-10-04","current":-0.40035,"twenty":-3.10757,"median":-0.969101,"eighty":-0.518359,"marketCap":3921358},{"date":"2024-10-11","current":-0.323812,"twenty":-3.074965,"median":-0.929813,"eighty":-0.510905,"marketCap":3171687},{"date":"2024-10-18","current":-0.453043,"twenty":-3.039851,"median":-0.929813,"eighty":-0.50063,"marketCap":4437478},{"date":"2024-10-25","current":-0.44745,"twenty":-3.004737,"median":-0.897073,"eighty":-0.496905,"marketCap":4382695},{"date":"2024-10-31","current":-0.387809,"twenty":-2.984671,"median":-0.887219,"eighty":-0.481006,"marketCap":3798527},{"date":"2024-11-08","current":-0.3768,"twenty":-2.921968,"median":-0.877429,"eighty":-0.4664,"marketCap":3690690},{"date":"2024-11-15","current":-0.384351,"twenty":-2.836692,"median":-0.854511,"eighty":-0.455716,"marketCap":3869549},{"date":"2024-11-22","current":-0.377927,"twenty":-2.658314,"median":-0.844689,"eighty":-0.443305,"marketCap":3804880},{"date":"2024-11-29","current":-0.365833,"twenty":-2.506623,"median":-0.825045,"eighty":-0.418071,"marketCap":3683114},{"date":"2024-12-06","current":-0.39577,"twenty":-2.470506,"median":-0.818497,"eighty":-0.40035,"marketCap":3984515},{"date":"2024-12-13","current":-0.412535,"twenty":-2.445424,"median":-0.753018,"eighty":-0.397566,"marketCap":4153299},{"date":"2024-12-20","current":-0.39098,"twenty":-2.326288,"median":-0.690812,"eighty":-0.394462,"marketCap":3936291},{"date":"2024-12-27","current":-0.395231,"twenty":-2.301709,"median":-0.659676,"eighty":-0.389674,"marketCap":3979090},{"date":"2025-01-03","current":-0.433118,"twenty":-2.127114,"median":-0.588632,"eighty":-0.388621,"marketCap":4360524},{"date":"2025-01-10","current":-0.604732,"twenty":-1.900137,"median":-0.571087,"eighty":-0.389195,"marketCap":6088291},{"date":"2025-01-17","current":-0.574794,"twenty":-1.658886,"median":-0.565435,"eighty":-0.389459,"marketCap":5786890},{"date":"2025-01-24","current":-1.670496,"twenty":-1.659719,"median":-0.576739,"eighty":-0.390022,"marketCap":16818150},{"date":"2025-01-31","current":-1.460936,"twenty":-1.611819,"median":-0.602629,"eighty":-0.391676,"marketCap":14708346},{"date":"2025-02-07","current":-0.946016,"twenty":-1.585135,"median":-0.66128,"eighty":-0.394604,"marketCap":9524257},{"date":"2025-02-14","current":-1.035827,"twenty":-1.538609,"median":-0.708819,"eighty":-0.395183,"marketCap":10428459},{"date":"2025-02-21","current":-0.975953,"twenty":-1.472911,"median":-0.759705,"eighty":-0.395231,"marketCap":9825657},{"date":"2025-02-28","current":-1.227426,"twenty":-1.46293,"median":-0.818497,"eighty":-0.39564,"marketCap":12357422},{"date":"2025-03-07","current":-1.261554,"twenty":-1.460936,"median":-0.821771,"eighty":-0.39577,"marketCap":12701019},{"date":"2025-03-14","current":-1.023852,"twenty":-1.460936,"median":-0.844689,"eighty":-0.397566,"marketCap":10307898},{"date":"2025-03-21","current":-0.880154,"twenty":-1.457355,"median":-0.854511,"eighty":-0.40035,"marketCap":8861176},{"date":"2025-03-28","current":-0.886141,"twenty":-1.4255,"median":-0.869975,"eighty":-0.40035,"marketCap":8921456},{"date":"2025-04-04","current":-1.077003,"twenty":-1.422191,"median":-0.878791,"eighty":-0.409475,"marketCap":8567922},{"date":"2025-04-11","current":-1.035801,"twenty":-1.409653,"median":-0.886141,"eighty":-0.412125,"marketCap":8240147},{"date":"2025-04-17","current":-0.962911,"twenty":-1.409589,"median":-0.89046,"eighty":-0.412453,"marketCap":7660285},{"date":"2025-04-25","current":-1.051146,"twenty":-1.409589,"median":-0.903563,"eighty":-0.416964,"marketCap":8362223},{"date":"2025-05-02","current":-0.959075,"twenty":-1.409573,"median":-0.923265,"eighty":-0.422024,"marketCap":7629766},{"date":"2025-05-09","current":-0.859331,"twenty":-1.402763,"median":-0.90833,"eighty":-0.427961,"marketCap":6836270},{"date":"2025-05-16","current":-0.796083,"twenty":-1.395129,"median":-0.890525,"eighty":-0.429622,"marketCap":5859660},{"date":"2025-05-23","current":-0.793678,"twenty":-1.387275,"median":-0.886141,"eighty":-0.43244,"marketCap":5841959},{"date":"2025-05-30","current":-0.851295,"twenty":-1.383247,"median":-0.882065,"eighty":-0.438609,"marketCap":6266057},{"date":"2025-06-06","current":-0.963307,"twenty":-1.371732,"median":-0.886141,"eighty":-0.445378,"marketCap":7090538},{"date":"2025-06-13","current":-1.200774,"twenty":-1.347174,"median":-0.890493,"eighty":-0.447945,"marketCap":8838439},{"date":"2025-06-20","current":-1.07532,"twenty":-1.332804,"median":-0.903563,"eighty":-0.450182,"marketCap":7915020},{"date":"2025-06-27","current":-1.048437,"twenty":-1.326316,"median":-0.914022,"eighty":-0.453938,"marketCap":7717144},{"date":"2025-06-30","current":-1.189405,"twenty":-1.324869,"median":-0.918643,"eighty":-0.454385,"marketCap":8754759}],"updateTime":1751593960463}}}